
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc. shows a promising outlook due to the efficacy of its bifunctional therapy, ficerafusp alfa, which demonstrates a significantly higher objective response rate (ORR) compared to established treatments like Keytruda. Specifically, ficerafusp alfa achieved superior clinical outcomes with notable metrics, such as a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, enhancing its therapeutic profile against similar patient populations. The comparative advantage in survival metrics implies a potential shift in treatment standards for patients with solid tumors, further supporting positive sentiment towards the stock.
Bears say
Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, aligning closely with prior estimates, and projects a full-year loss of $2.27 per share, a slight improvement from previous forecasts. The company faces significant risks, including the potential for negative clinical results with its lead program ficerafusp alfa, delays in moving the treatment to registrational trials, and challenges in achieving timely regulatory approvals. Furthermore, the competitive landscape poses additional challenges, with risks of long-term dilution also impacting investor sentiment regarding the stock.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares